

REMARKS

The July 11, 2005 Office Action called for restriction from among the following groups:

- I. Claims 1-19, drawn to a transgenic animal model to which a regucalcin gene is introduced and over expressed, a screening method of preventive and therapeutic agents, and a therapeutic agent, classified in class 800, subclass 8;
- II. Claims 1-12 and 20-24, drawn to a transgenic animal model to which a regucalcin gene is introduced and over expressed, a screening method of causative agents of disease, and a causative agent, classified in class 800, subclass 8.
- III. Claims 25-40, drawn to an animal model having bone pathology, wherein the animal model over expresses regucalcin and shows bone pathology, a screening method of preventive and therapeutic agents, and a therapeutic agent, classified in class 435, subclass 325.

In response to the requirement for restriction, Applicants hereby elect the claims of group III, i.e. claims 25-40.

By this paper claims 2 and 33 have been amended to correct typographical errors, and claim 34 has been cancelled because it was an unintentional duplication of claim 33. No new matter is added by these amendments. It is submitted that the claims herewith are patentably distinct over the prior art, and these claims are in full compliance with the requirements of 35 U.S.C. §112. The amendments to the claims presented herein are not made for purposes of patentability within the meaning of 35 U.S.C. §§§§101, 102, 103 or 112. Rather, these additions are made simply to correct minor errors.

CONCLUSION

Early and favorable consideration of the application on the merits, and early Allowance of the application are earnestly solicited.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By: Deborah L. Lu
Thomas J. Kowalski
Reg. No. 32,147
Deborah L. Lu
Reg. No. 50,940
Telephone: (212) 588-0800
Facsimile: (212) 588-0500